Wave Life Sciences will host a webcast on March 4, 2025, to discuss Q4 2024 financial results and updates.
Quiver AI Summary
Wave Life Sciences Ltd. will host a live webcast and conference call on March 4, 2025, at 8:30 a.m. ET to discuss its fourth quarter and full year 2024 financial results along with business updates. Interested participants can access the event via the company’s website and register for the Q&A session through an audio conferencing link. Following the event, an archive of the webcast will be available online. Wave Life Sciences is a biotechnology company specializing in RNA medicines, leveraging its PRISM® platform to develop therapies for various disorders, including Alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy. The company's mission is to enhance human health by overcoming the challenges posed by diseases through innovative RNA-targeting technologies.
Potential Positives
- Wave Life Sciences will host a live webcast to review its fourth quarter and full year 2024 financial results, demonstrating transparency and engagement with investors.
- The company is focused on RNA medicines, a significant and emerging area in biotechnology with the potential to transform human health.
- Wave's diversified pipeline includes clinical programs addressing various serious conditions, indicating a strong commitment to tackling unmet medical needs.
- The company emphasizes its innovative PRISM® platform, underscoring its capabilities in RNA-targeting modalities, which could position it competitively in the biotechnology space.
Potential Negatives
- None
FAQ
When is the Wave Life Sciencesearnings callscheduled?
Theearnings callis scheduled for March 4, 2025, at 8:30 a.m. ET.
How can I access the webcast for the earnings review?
You can access the webcast by visiting the “Investor Events” section on the Wave Life Sciences website.
What financial results will Wave Life Sciences discuss?
Wave Life Sciences will review its fourth quarter and full year 2024 financial results during the call.
What topics will be covered in the conference call?
The call will cover financial results and provide business updates related to Wave Life Sciences' operations.
How can analysts participate in the Q&A section of the call?
Analysts can join the Q&A by registering via the provided audio conferencing link to receive dial-in information.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$WVE Insider Trading Activity
$WVE insiders have traded $WVE stock on the open market 10 times in the past 6 months. Of those trades, 1 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $WVE stock by insiders over the last 6 months:
- PLC GSK purchased 2,791,930 shares for an estimated $22,335,440
- CHRIS FRANCIS (See Remarks) has made 0 purchases and 5 sales selling 244,836 shares for an estimated $3,431,050.
- PAUL BOLNO (President and CEO) has made 0 purchases and 3 sales selling 191,708 shares for an estimated $2,840,780.
- KYLE MORAN (Chief Financial Officer) sold 17,146 shares for an estimated $154,314
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$WVE Hedge Fund Activity
We have seen 115 institutional investors add shares of $WVE stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARTAL GROUP S.A. removed 4,566,251 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $37,443,258
- BLACKROCK, INC. added 2,061,740 shares (+28.2%) to their portfolio in Q4 2024, for an estimated $25,503,723
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,972,262 shares (+63.1%) to their portfolio in Q4 2024, for an estimated $24,396,880
- SIREN, L.L.C. removed 1,970,681 shares (-34.4%) from their portfolio in Q4 2024, for an estimated $24,377,323
- MAVERICK CAPITAL LTD removed 1,786,278 shares (-17.8%) from their portfolio in Q4 2024, for an estimated $22,096,258
- LOOMIS SAYLES & CO L P added 1,660,866 shares (+inf%) to their portfolio in Q4 2024, for an estimated $20,544,912
- TAKEDA PHARMACEUTICAL CO LTD removed 1,346,892 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $16,661,054
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, March 4, 2025, to review the company’s fourth quarter and full year 2024 financial results and provide business updates.
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website:
https://ir.wavelifesciences.com/events-publications/events
.
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link:
available here
. Once registered, participants will receive the dial-in information.
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM
®
, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and Obesity, as well as several preclinical programs utilizing the company’s broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. For more information on Wave’s science, pipeline and people, please visit
www.wavelifesciences.com
and follow Wave on
X
(formerly Twitter) and
LinkedIn
.
Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com
Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
